Publication including Exscientia’s Chief Chemist Andy Bell, describes a potential new treatment for the common cold

Exscientia, is delighted to note that its Chief Chemist Andy Bell, who previously led a medicinal chemistry team at Imperial College, has published ground-breaking work that identifies novel molecules to treat the common cold.

The research, published in Nature Chemistry, describes work behind the design of IMP-1088, a novel and highly potent anti-viral that prevents the cold virus from making new copies of itself. By targeting a human protein (N-myristoyltransferase) rather than a cold virus protein, the emergence of drug resistance to IMP-1088 is expected to be minimised. Further research leading to human clinical trials is anticipated.
To learn more, see the announcement by Imperial College and the original publication.

Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.

Evotec Invests in Exscientia to advance AI-driven Drug Discovery

  • Evotec to invest € 15 M in Exscientia, A pioneer of Artificial Intelligence (“AI”) in drug discovery
  • New funds will enable Exscientia to accelerate growth
  • Expansion of existing partnership to discover novel immuno-oncology therapeutics
  • First Evotec project supported by recent € 75 M loan facility from the European Investment Bank

Hamburg, Germany, Dundee, UK: 28 September 2017
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Exscientia Ltd (“Exscientia”) today announced that Evotec has made a € 15 M investment to take a minority stake in Exscientia. Through this investment, Evotec becomes the first strategic shareholder in the UK based company. Exscientia is focused on Artificial Intelligence (“AI”)-driven drug discovery and design. With more than 1800 scientists, Evotec has one of the largest and leading drug discovery platforms in the industry.

Exscientia Enters Strategic Drug Discovery Collaboration with GSK

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.

Exscientia will receive research payments from GSK to undertake new discovery programmes with nominated targets with the goal of delivering pre-clinical candidates. In addition to research funding, Exscientia is eligible to receive near-term lead and pre-clinical candidate milestones if all objectives are achieved. The total amount payable by GSK to Exscientia on achieving these milestones is £33 million, if all 10 projects are advanced. No further financial details have been disclosed.



Exscientia社 (エクセンシア)は、AI創薬の先頭を行く革新的な会社ですが、この度グラクソ・スミスクライン(GSK)との戦略的創薬研究契約を締結しましたので、お知らせします。この戦略的提携はExscientiaが有するAI創薬とGSKの創薬経験を融合してGSKが指定する最大10の疾患関連創薬標的に対する画期的かつ選択的な低分子医薬品の研究開発をすることを目的としています。

Exscientia社は、GSKが指定する標的タンパク質に対して、医薬品候補化合物に到達することを目的とする創薬プログラムの実施の対価として、GSKから研究資金を受領します。 研究資金提供に加えて、すべての目的が達成されるならば、Exscientia社はnear-term leadと医薬品候補化合物達成のマイルストーンを受ける資格があります。 10の全てのプロジェクトが進展して、これらのマイルストーンが達成されるとExscientia社へGSKからGBP£3300万が支払われる契約になっています。 さらなる契約金の詳細については明らかにされていません。